![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HIV and Cancer Curative Approaches
Cross-disciplinary research
|
|
|
Steven Deeks, MD
Professor of Medicine
University of California, San Francisco
Reported by Jules Levin
Glasgow Oct 27-31 2018
Glasgow Oct 27-31 2018
![1109181](../images%20/110918/110918-2/1109181.gif)
![1109182](../images%20/110918/110918-2/1109182.gif)
![1109183](../images%20/110918/110918-2/1109183.gif)
![1109184](../images%20/110918/110918-2/1109184.gif)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002417
Conclusions
We report HIV relapse despite initiation of ART at one of the earliest stages of acute HIV infection possible. Near complete or complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission. However, the small numbers of latently infected cells in individuals treated during hyperacute infection may be associated with prolonged ART-free remission.
What did the researchers find?
°No HIV could be definitively detected for up to 2 years in the participant who initiated ART approximately 10 days after HIV infection.
°Intermittent, very low levels of HIV were detected in blood but not tissue in the participant who initiated ART an estimated 12 days following infection.
°The participant with no detectable HIV following ART experienced viral rebound 225 days after stopping ART.
What do these findings mean?
°HIV relapsed despite initiation of ART at one of the earliest stages of acute HIV infection possible.
°Near complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission.
-----------------------
![1109185](../images%20/110918/110918-2/1109185.gif)
![1109186](../images%20/110918/110918-2/1109186.gif)
![1109187](../images%20/110918/110918-2/1109187.gif)
![1109189](../images%20/110918/110918-2/1109189.gif)
![11091810](../images%20/110918/110918-2/11091810.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|